ReviewFrontiers in chemistry2022
Biogenic silver nanoparticles as antifungal agents.
Review in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 65 citations in OpenAlex.
- Biogenic Silver Nanoparticle: In vitro antifungal activity against Sporothrix brasiliensis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Kombucha-Mediated Silver Nanoparticles with Fungicidal Activity Against WHO-PriorityCurrent issues in molecular biology · 2026Article
- Synergistic Liposomal Delivery of Ibrexafungerp Citrate and Marine-Sourced Silver Nanoparticles for Effective Management of Vulvovaginal Candidiasis.Journal of functional biomaterials · 2026Article
- Antifungal Efficacy of Chlorhexidine Digluconate and Silver Nanoparticles Incorporated into Molloplast-B Silicone Soft Liner Against Candida albicans: An In Vitro Study.Journal of clinical and experimental dentistry · 2026Review
- Green Synthesis and Characterization of Silver Nanoparticles UsingInternational journal of microbiology · 2026Article
- Heparin-Conjugated Silver Nanoparticles via Amide Chemistry for Selective Targeting of Triple-Negative Breast Cancer and Pathogenic Fungi.International journal of nanomedicine · 2026Article
- Harnessing Nanoparticles and Nanosuspensions to Combat Powdery Mildew: A Frontier in Vegetable and Fruit Protection.Journal of fungi (Basel, Switzerland) · 2025Review
- Unravelling azole resistance in fungal pathogens: molecular mechanisms, diagnostic challenges, and therapeutic strategies.World journal of microbiology & biotechnology · 2025Review
- Label-Free Quantitative Proteomic Analysis Reveals the Effects of Biogenic Silver Nanoparticles onACS omega · 2025Article
- Mycogenic Silver Nanoparticles: Promising Antimicrobials with Fungistatic Properties.International journal of molecular sciences · 2025Article
- Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.Small science · 2025Article
- Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Chitosan-Coated Silver Nanocomposites: Biosynthesis, Mechanical Properties, and AgInternational journal of molecular sciences · 2025Article
- Ecotoxicity of fungal-synthesized silver nanoparticles: mechanisms, impacts, and sustainable mitigation strategies.3 Biotech · 2025Review
- Silver Nanoparticles: A Versatile Tool Against Infectious and Non-Infectious Diseases.Antibiotics (Basel, Switzerland) · 2025Review
- AgNPs biosynthesized fromFrontiers in microbiology · 2025Article
- Extracellular Biosynthesis, Characterization and Antimicrobial Activity of Silver Nanoparticles Synthesized by Filamentous Fungi.Journal of fungi (Basel, Switzerland) · 2024Article
- Unlocking the Potential of Silver Nanoparticles: From Synthesis to Versatile Bio-Applications.Pharmaceutics · 2024Review
- The antimicrobial effects of silver nanoparticles obtained through the royal jelly on the yeasts Candida guilliermondii NP-4.Scientific reports · 2024Article
- Synergistic Antimicrobial Activity of Biogenic Silver Nanoparticles andAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, an increase in multidrug-resistant fungal strains has been observed, which, together with the limited number of clinically available antifungal agents, highlights the need for the development of new antifungal agents. Due to the proven antifungal activity of silver nanoparticles (AgNPs), there is a growing interest in their use in the treatment of fungal infections. Nanoparticles are usually synthesised through a variety of physical and chemical processes that are costly and pollute the environment. For this reason, biogenic synthesis is emerging as an environmentally friendly technology and new strategies are increasingly based on the use of biogenic AgNPs as antifungal agents for clinical use. The aim of this review is to compare the antifungal activity of different biogenic AgNPs and to summarise the current knowledge on the mechanisms of action and resistance of fungi to AgNPs. Finally, a general analysis of the toxicity of biogenic AgNPs in human and veterinary medicine is performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.